failur rova-t game changer
downgrad rate hold also tp
tp base forward price-to-earnings multipl
adjust ep provid
upsid potenti expect top-
line revenu grow
demonstr except track record
market competit challeng anoth
clear exampl perform estim base
follow factor strong growth revenu
earn launch ramp sever new product strong
growth sever key product studi rova
halt
bought stemcentrx up-front
payment cancer drug rova decemb
phase studi product halt led
impair charg rais concern
regard acquisit growth compani
studi rova-t crucial factor growth
failur studi rova affect
growth result reduc tp
also result fall stock price sinc decemb
total revenu increas
estim adjust ep increas
in-lin estim
mn except
compani nameabbvi inc tickerabbvstock ratingholddowngradeindustri viewoverweightpositivepric week week volum volum mrq n/aforward ep gin gin ttm per share growth profit ttm ttm incom ttm earn growth yoy n/acrispideaakansha abbvi inc ch
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
growth driven number product includ
hematolog oncolog portfolio global oper
sale growth humira
grew compar
intern humira sale nearli
reflect impact direct biosimilar competit
europ intern market saw
continu strong perform sever product
includ mavyret creon duodopa
hematolog oncolog built powerhous
franchis imbruvica venclexta franchis
roughli growth expect
signific growth anticip long-rang
secur regulatori approv sever program
includ venclexta broad relapse/refractori cll
popul condit approv venclexta
newli diagnos aml patient inelig intens
also got approv imbruvica combin
rituxan first chemotherapy-fre combin
treatment waldenstrm fda approv
imbruvica overal orilissa manag
moderate-to-sever pain associ endometriosi
recommend hold rate tp
base perform product portfolio
expect ep
adjust ep expect
growth revenu per compani
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior month error dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date may ex-dividend date apr last split factor new per old n/a last split date n/atrad inform inc march
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
non- reconcili refer page
incom statement item total gross research develop sell gener administr sg oper profit interest incom interest incom incom incom net incom outstand dilut ep dilut ep actual annual estim annual actual quarterli abbvi inc march
 market account receivable- total prepaid current assets- total current build machineri furnitur total fix non-curr defer incom taxes- non-curr total non-curr total equiti liabilitiesaccount accru defer revenues- current liabilities- total current long-term defer incom taxes- non-curr minor interest total non-curr liabilities- total liabilities- prefer stock equity- common stock addit paid-in retain treasuri total total total liabil stock actual annual actual quarterli balanc sheet item abbvi inc march
oper cash flow increas compar due improv
result oper revenu growth decreas incom tax payment
flow invest activ increas compar
includ payment made acquisit invest capit expenditur
flow financ activ compar includ
proce issuanc term loan credit agreement term loan enter
defer incom taxes- oper increas decreas increas decreas current assets- decreas increas payables- decreas increas current liabilities- decreas increas work capital- non- net continu net discontinu operations- net total oper invest activitiessal properti plant equipment- purchas properti plant net invest financ activitiesissu issuanc capit stock- repurchas capit payment financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end abbvi inc march
abbvi inc deliv strong financi result advanc invest
pipelin total revenu increas year due strong growth
key product mavyret imbruvica venclexta humira
total revenu increas compar
due continu strength humira revenu
growth relat imbruvica hcv product mavyret world-wide
adjust net revenu increas oper basi exclud
unfavor impact foreign exchang
total revenu increas
compar previou year quarter total intern revenu
decreas compar previou year
quarter
cog increas compar
basi gross margin ratio
adjust gross margin ratio
sg expens decreas compar
basi sg expens net
revenu adjust sg expens net revenu
 expens increas compar
basi expens net revenu
adjust expens reflect fund action
support stage pipelin acquir in-process
compar
oper loss compar oper incom
basi oper margin
adjust oper margin gaap
basi net interest expens compar
total revenu
increas
compar
oper loss
compar oper
incom
incom compar expens
basi tax rate
adjust tax rate
item increas
compar
net loss compar net incom
dilut loss per share basi inclus
recent partial impair charg relat intang asset acquir
part acquisit stemcentrx inc adjust dilut ep exclud
specifi item increas compar
total revenu
increas
compar
total revenu increas compar
due continu strength humira revenu
growth relat imbruvica hcv product mavyret
total revenu increas
compar prior-year period total intern revenu increas
compar
cog increas compar
gross profit increas compar
gross margin net revenu compar
gross margin net revenu increas due reduct
humira royalti expens intang asset impair charg
partial off-set imbruvica profit share arrang
sg expens increas compar
sg expens net revenu increas
compar increas due unfavor impact
new product launch expens charit contribut
select not-for-profit organ part previous
announc plan partial off-set continu leverag revenu growth
 expens increas compar
 expens increas due intang asset impair
charg relat ipr acquir part stemcentrx acquisit
follow decis stop enrol taho trial impair
due lower probabl success achiev regulatori approv
across rova-t early-stag asset obtain acquisit
remain increas reflect greater fund support stage
expens relat extens
collabor discov develop bring market new therapi
patient acquir in-process expens compar
oper earn compar
interest expens net compar
interest expens increas due unfavor impact higher interest
rate compani debt oblig higher averag outstand debt
balanc
net foreign exchang loss compar
expens net compar
expens net includ charg relat chang fair valu
bi stemcentrx conting consider liabil
effect incom tax rate compar
effect tax rate reflect impact effect date
provis tax cut job act act relat earn
certain foreign subsidiari effect stemcentrx intang impair
due
relat ipr
acquir part
acquisit follow
decis stop
enrol taho
net earn increas compar
dilut ep compar dilut
earn per share includ follow after-tax cost
stemcentrx-rel impair charg net relat fair
valu adjust conting consider liabil
ii intang asset amort
compar
dilut
ep
compar
iii result collabor agreement extens calico life
iv acquir in-process research develop ipr
 chang fair valu conting consider liabil
exclud fair valu adjust associ stemcentrx-rel
vi litig reserv charg
vii charit contribut part previous
announc plan make contribut not-for-profit organ
viii mileston payment financi result also
impact tax reform time new legisl phase
certain subsidiari addit financi result reflect continu
ad fund support stage abbvi emerg pipelin asset
continu invest growth brand
total revenu
humira increas
compar
total revenu
humira increas
compar
abbvi product focus treat condit chronic
autoimmun diseas rheumatolog gastroenterolog dermatolog
oncolog includ blood cancer virolog includ hepat hcv
human immunodefici viru hiv neurolog disord
parkinson diseas metabol diseas includ thyroid diseas
complic associ cystic fibrosi well seriou health
total revenu humira increas
compar total revenu increas
compar increas due
market growth across therapeut categori geographi well
favor price certain geographi
total revenu increas
compar total intern revenu increas
compar
imbruvica venclexta
total revenu imbruvica increas
compar total revenu increas
compar increas due continu
penetr imbruvica patient chronic lymphocyt leukemia
cll well favor price
total revenu increas
compar total collabor revenu increas
compar
total revenu
venclexta increas
compar
total revenu venclexta increas
compar total revenu increas
compar growth due
market share gain follow fda ema approv venclexta
combin rituxan certain patient r/r cll
total revenu increas
compar total intern revenu increas
compar
total revenu mavyret increas
compar total revenu increas
compar growth due
market share gain follow fda ema approv mavyret
well geograph expans
compar
total revenu increas
compar total intern revenu increas
compar
total revenu viekira decreas
compar total revenu declin
compar growth due lower
market share follow launch mavyret
total revenu declin
compar total intern revenu declin
compar
total revenu
creon increas
compar
total revenu
synthroid increas
compar
total revenu creon increas
compar total revenu increas
compar growth due
continu market growth higher market share
total revenu kaletra increas
compar total revenu decreas
compar
total revenu decreas
compar total intern revenu increas
compar
total revenu synagi decreas
compar total revenu increas
compar
total revenu androgel decreas
compar total revenu decreas
compar decreas due market
contract entri gener competit androgel
formul octob
total revenu synthroid increas
compar total revenu decreas
compar
total revenu lupron increas
compar total revenu increas
compar
total revenu increas
compar total intern revenu increas
compar
total revenu duodopa increas
compar total revenu increas
compar
total revenu increas
compar total intern revenu increas
compar increas
revenu due increas market penetr
total revenu sevofluran decreas
compar total revenu decreas
compar total revenu
declin compar total
intern revenu declin compar
compar
total revenu
compar
announc
 food drug
approv venclexta
venetoclax
combin
azacitidin
decitabin low-dos
cytrabin ldac
treatment newly-
announc food drug administr fda grant
acceler approv venclexta venetoclax combin
azacitidin decitabin low-dos cytrabin ldac treatment
newly-diagnos acut myeloid leukemia aml adult age
year older comorbid preclud use intens
continu approv venclexta may conting upon verif
descript clinic benefit confirmatori trial expect
complet approv aml third provid prioriti
review fda venclexta grant four breakthrough
therapi design btd fda venetoclax develop
roch jointli commerci genentech
member roch group outsid
announc european commiss ec approv type-ii
variat applic venclyxto venetoclax combin
rituximab treatment patient relapsed/refractori r/r chronic
lymphocyt leukemia cll receiv least one prior therapi
approv allow patient receiv venclyxto combin
rituximab second-lin set also give healthcar provid
abil prescrib medicin broader popul patient r/r
cll previous approv indic venclyxto monotherapi
european union approv base result phase
murano trial demonstr statist signific improv
investigator-assess progression-fre surviv patient receiv
venclyxto plu rituximab compar bendamustin plu rituximab
announc top-line result phase resolv trial
imbruvica combin nab-paclitaxel gemcitabin versu
placebo combin chemotherapi agent patient
metastat pancreat adenocarcinoma cancer conclus studi
meet primari endpoint improv os benefit among studi
phase
reduct
risk progress
american societi hematolog annual meet exposit
present data nearli abstract includ oral
present poster present multipl studi
investig venclexta imbruvica ibrutinib across number
hematolog malign present includ updat result
phase murano trial venetoclax combin rituximab patient
r/r cll show treatment venclexta rituximab
provid sustain benefit minim residu follow addit
year follow-up data
collabor partner present new updat imbruvica
data meet includ result three phase studi
patient previous untreat cll phase trial
imbruvica plu obinutuzumab significantli prolong
reduct risk progress death versu chlorambucil plu
phase trial imbruvica plu rituximab significantli
prolong improv overal surviv os compar fludarabin
cyclophosphamid rituximab fcr previous untreat younger
patient cll phase allianc trial imbruvica alon
combin rituximab produc superior compar
bendamustin plu rituximab br untreat older patient cll also
featur seven-year data patient treat imbruvica
show durabl respons sustain rate imbruvica
cll/sll small lymphocyt lymphoma previous untreat patient
follow decis stop enrol taho trial phase studi
evalu rovalpituzumab tesirin rova-t second-lin therapi
advanc small-cel lung cancer sclc evalu stemcentrx-
relat intang asset record impair charg relat
intang asset acquir part acquisit stemcentrx inc
after-tax net impact impair relat adjust
conting consider liabil continu
evalu inform respect stemcentrx-rel clinic
develop program monitor remain intang
asset impair
announc
submit new drug
applic nda
fda market
european
medicin agenc
upadacitinib oral
select inhibitor
treatment adult
patient moder
sever rheumatoid
announc submit new drug applic nda
fda market author applic european
medicin agenc upadacitinib oral investig
inhibitor treatment adult patient moder sever
nda support data global upadacitinib select
phase rheumatoid arthriti program evalu patient
moder sever rheumatoid arthriti across five phase studi
select program result show upadacitinib improv sign
symptom rheumatoid arthriti inhibit radiograph progress
improv physic function monotherapi combin
american colleg rheumatolog acr /associ rheumatolog
health profession arhp annual meet present new data
upadacitinib humira abstract present across multipl
juvenil idiopath arthriti uveiti includ present data
three five pivot studi select phase program
unit european gastroenterolog week uegw confer
showcas gastroenterolog portfolio present humira
pipelin data includ first present data phase studi u-
achiev evalu upadacitinib adult patient moder sever
activ ulcer coliti result u-achiev studi demonstr
week upadacitinib mg daili met primari
endpoint clinic remiss per adapt mayo score rank secondari
mayo score clinic respons
announc global resolut intellectu property-rel
litig momenta propos biosimilar
adalimumab product term settlement agreement abbvi
grant momenta non-exclus licens intellectu
properti relat humira begin certain date certain countri
intellectu properti
result phase
show
week mavyret
genotyp
patient
week treatment
american associ gynecolog laparoscopist aagl global
congress minim invas gynecolog cooper
present addit result two replic
pivot phase clinic trial elari elari evalu
efficaci safeti elagolix women uterin fibroid
result demonstr final month six-month treatment
period elagolix combin low-dos hormon add-back therapi
reduc heavi menstrual bleed associ uterin fibroid compar
placebo data phase clinic trial program support regulatori
submiss elagolix uterin fibroid anticip
annual meet american associ studi liver
diseas aasld present new data pan-genotyp chronic
hepat viru hcv treatment mavyret glecaprevir/pibrentasvir
treatment-nav patient compens cirrhosi result phase
studi show week mavyret
genotyp patient achiev sustain virolog respons
week treatment per protocol analysi mavyret current approv
pan-genotyp treatment treatment-nav patient without
licens period begin novemb
momenta acceler entri compani
alreadi taken licens momenta pay royalti
licens humira patent manufactur acknowledg
valid licens patent make payment
momenta enter total seven settlement
agreement manufactur relat licens propos biosimilar
announc board director author increas
contribut total includ donat st
jude children research hospit enhanc expand patient family-
center care made total charit
contribut non-for-profit organ
issu ep guidanc
guidanc reflect non-cash charg conting
consider adjust relat expect approv risankizumab
expect deliv adjust dilut ep
repres growth mid-point abbvi adjust dilut
ep guidanc exclud per share intang asset amort
expens non-cash charg conting consider adjust
specifi item
expect revenu growth oper basi
current rate would expect foreign exchang less
unfavor impact report sale growth
issu
ep guidanc
revenu growth
oper basi
continu drive strong commerci oper execut
result global oper sale growth
adjust earn per share growth
growth driven number product includ hematolog
oncolog portfolio global oper sale growth
 humira grew compar
intern humira sale nearli reflect impact
direct biosimilar competit europ intern market
also saw continu strong perform sever product
includ mavyret creon duodopa
secur regulatori approv sever program includ
venclexta broad relapse/refractori cll popul condit
approv venclexta newli diagnos aml patient inelig
got approv imbruvica combin rituxan first
chemotherapy-fre combin treatment waldenstrm fda
approv imbruvica overal orilissa manag
moderate-to-sever pain associ endometriosi
year clearli demonstr investor
deliv commit absorb roughli
eros relat biosimilar competit roughli
addit impact follow entri gener competit androgel
also fund five major product indic
continu
oper
execut result
sale growth
adjust
growth
non- reconcili
non- reconcili
non- reconcili
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
gross margin increas compar
oper margin declin compar due increas
net margin compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth abbvi inc march
mrqgross mrqoper mrqnet mrqcog mrqr mrqsg sale abbvi inc march
invest flow
sale
mrqyoy growth revenu growthoper incom growthep mrq ratio growth yoy oper growth yoy free growth mrqcapex salescap ex salesfre mrqfinanci mrqreturn mrqreturn asset inc march
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom discontinued- net net margin prefer dividends- annual itemsquarterli item abbvi inc march
balanc sheet ratio
outstand equival market debt common prefer stock- purchas properti plant sale properti plant equipment- purchas sale business- purchas sale issuanc stock- repurchas net issuanc prefer stock- net issuanc net chang capit free abbvi inc march
current price-to-earnings lower price-to-earnings trail
past
price-to-earnings fallen due fall stock price result failur drug rova
acquir
price-to-earnings surg januari due rise stock price averag
price-to-earnings expect forward price-to-earnings
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold institut holdersholdersharesd report outvaluecapit research global vanguard group inc northern trust capit world geod capit manag orbi gray top mutual fund holdersholdersharesd report outvalueinvest compani vanguard total stock market capit incom builder growth fund america vanguard capit world growth incom amcap spdr etf american mutual fund vanguard institut fund-institut competit
developmentsabbvi provid updat venclexta/venclyxto venetoclax multipl myeloma programmarch announc food drug administr fda place partial clinic hold clinic trial evalu venetoclax venclexta/venclyxto investig treatment multipl myeloma partial clinic hold follow review data on-going phase bellini trial studi relapsed/refractori multipl myeloma higher proport death observ venetoclax arm compar control arm trial result action new patient enrol studi venetoclaxfor multipl myeloma analysi data complet patient current enrol studi receiv benefit therapi may continu treatment consult physician abbvi receiv chmp posit opinion risankizumab skyrizi treatment moder sever plaqu psoriasismarch announc european medicin agenc ema committe medicin product human use chmp adopt posit opinion skyrizi risankizumab investig inhibitor treatment moder sever plaqu psoriasi adult patientswho candid system therapi abbvi announc collabor develop vector antibodi treat parkinson diseas synucleinopathiesfebruari inc clinical-stag gene therapi compani focus develop life-chang treatment sever neurolog diseas today announc exclus global strateg collabor option agreement develop commerci vector antibodi direct patholog speci alpha-synuclein potenti treatment parkinson diseas diseas synucleinopathi character abnorm accumul misfold alpha-synuclein protein abbvi tizona therapeut announc strateg collabor develop first-in-class immunotherapi cancer target tizona therapeut inc privat held immunotherapi compani announc enter global strateg collabor develop commerci therapeut includ first-in-class antibodi treatment cancer abbvi inc march
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
perform
compar
roa roi
respect
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit consensu view analyst trend stock
forecast
higher
compar
forward price-to-earnings
lower
compar
annual usdgrowth high day day day estim avgfive-year growth forecast comparisonabbvindustri avg avgprice/earn yield consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr
next qtr
averag revenu estim
current qtr
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr growth ratescurr surprisescurr analyst recommend
price target summarycrispidea capit maintainsunderperformunderperformrecommend trendscurr monthlast monthtwo month agothre month agostrong estcurr qtr next qtrcurrent yearnext estcurr qtr next qtrcurrent yearnext abbvi inc march
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
stock price volatil period dip januari due week
guidanc given compani
stock declin period averag volum trade
stock saw huge fluctuat year low januari week
guidanc compani
high stock declin past
stock price show upward trend till januari later declin year
volatil due uncertainti drug acquir
stock given return past due growth busi
abbvi deliv strong perform year due growth advanc portfolio
includ signific contribut humira total revenu increas
imbruvica mavyret contrari failur studi rova affect growth
result reduc tp also result fall stock price sinc
decemb recommend hold rate stock base perform
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
